AARC has contacted CMS to request clarification on their policies for the reimbursement of Brovana (arfomoterol) in the home care setting. Brovana, a new long-acting beta agonist (LABA), has recently been introduced, but has not yet been assigned a reimbursement code for home use. [click link for full article]
More...